Pramlintide
Also known as: Symlin, Amylin analog
An amylin analog that slows gastric emptying and promotes satiety. FDA-approved for diabetes; studied for weight loss and metabolic control.
Beginner Basics
Plain-English guide to Pramlintide
What it does
This peptide slows down how fast your stomach empties food into your intestines and makes you feel fuller longer. Researchers study it because it helps control blood sugar spikes after eating and can reduce how much people eat overall.
Typical dose
Researchers typically start with 15 micrograms injected under the skin right before meals, then gradually increase by 15 micrograms every few days up to 30-60 micrograms per meal, with a maximum of 120 micrograms per injection.
When to inject
Inject immediately before your three main meals (breakfast, lunch, and dinner) when you're about to eat solid food.
Storage
Keep the dry powder in a cool, dark place until you mix it. Once mixed with the included liquid, store in the refrigerator and use within 28 days.
First-timer tip
Start at the lowest dose and increase slowly as directed-going too fast with this one commonly causes nausea, so patience with the ramp-up is your friend.
On This Page
Research Status
FDA-approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs in 30-50% of users during the first 1-2 weeks of therapy. Usually resolves spontaneously as tolerance develops. Eating smaller meals and avoiding high-fat foods may help. If severe, dose titration can be slowed.
Reported in 5-10% of users, typically during initial titration. Usually resolves within 1-2 weeks. Slower titration schedules may reduce incidence.
Risk is highest during the first 2-4 weeks of therapy. Insulin doses typically require reduction of 10-50% when pramlintide is initiated. Patients must monitor blood glucose closely and be trained to recognize and treat hypoglycemia. Pramlintide itself does not cause hypoglycemia but enhances insulin's glucose-lowering effect.
Occurs in 1-5% of users. Usually mild and transient. Proper site rotation and injection technique minimize risk. Ensure skin is completely dry before injection.
Reported in 2-5% of users. Usually mild and self-resolving. May be related to initial metabolic changes or dehydration.
Occurs in 1-3% of users, often related to hypoglycemia or rapid blood glucose changes. Ensure adequate carbohydrate intake and monitor blood glucose.
Reported in 2-5% of users. Usually mild and transient. May be related to slowed gastric emptying. Eating smaller, more frequent meals may help.
Extremely rare (<0.1% of users). Symptoms include difficulty breathing, swelling of face/throat, severe rash, or rapid heartbeat. Seek emergency medical attention immediately. Pramlintide is contraindicated in patients with known hypersensitivity to pramlintide or any component of the formulation.
Very rare but documented in post-marketing surveillance. Symptoms include severe abdominal pain, elevated amylase/lipase, and nausea. Seek immediate medical evaluation if severe abdominal pain develops. Pramlintide is contraindicated in patients with a history of pancreatitis.
Pramlintide slows gastric emptying and is contraindicated in patients with severe gastroparesis. Use with caution in patients with mild-to-moderate gastroparesis. Monitor for worsening symptoms such as persistent nausea, vomiting, or abdominal bloating.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 15-120 mcg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 3949 Da |
| Half-life | 48 minutes (subcutaneous) |
| Sequence | Members only |
Pramlintide is a synthetic analog of amylin, a hormone co-secreted with insulin that regulates postprandial glucose excursions. It acts on amylin receptors in the brain and gastrointestinal tract to slow gastric emptying, suppress glucagon secretion, and promote satiety, thereby reducing postprandial blood glucose spikes and overall caloric intake. These effects complement insulin action and improve glycemic control in both type 1 and type 2 diabetes.
Track your Pramlintide research
Free account. No credit card required.
Recent Research
Pramlintide.
Metal-tuned antimicrobial peptides and zincophore pathways: from coordination chemistry to targeted therapeutics.
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Research Citations
5 sources
Edelman SV, Weyer C. Unexamined aspects of GLP-1 receptor agonist therapy in type 2 diabetes. Clin Ther. 2018;40(3):410-421. PMID: 29395618 — Discusses amylin analogs and GLP-1 agonists in metabolic control.
Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with existing therapies. Clin Ther. 2004;26(5):680-691. PMID: 15220012 — Clinical efficacy and mechanism of pramlintide in both diabetes types.
Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 20-week study. Diabetes Care. 2003;26(3):784-790. PMID: 12610037 — Demonstrates weight loss and glycemic benefits in type 2 diabetes.
Kolterman OG, Gottlieb A, Moyses C. Pramlintide in patients with type 1 diabetes: association with reduced severity of hypoglycemic events. Diabetes Care. 2003;26(3):798-804. PMID: 12610039 — Safety profile and hypoglycemia reduction.
Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide in patients with type 1 diabetes. Diabetes Care. 2002;25(4):724-730. PMID: 11919131 — Long-term efficacy and tolerability data.
Related: Metabolic & Weight Loss
Browse the Research Library
133 peptide profiles and 54 blend profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesStay updated on Pramlintide research
Weekly digest of new peptide research, stack guides, and platform updates.
Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Pramlintide is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.